Back to search
FDAFDA · Food and drugs·Recall number D-1601-2020

Nature-Throid, Thyroid USP [liothyronine (T3) 15.75 mcg and levothyroxine (T4) 66.5 mcg], 1.75 Grain (113.75 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3307-4; b) 60-count bottles, NDC 64727-3307-5; c) 90-count bottles, NDC 64727-3307-6; d) 100-count bottles, NDC 64727-3307-1; and e) 1,000-count bottles, NDC 64727-3307-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034.

Published September 23, 2020 · Recall initiated: August 25, 2020

Summary

FDA records drug Class II recall D-1601-2020, published September 23, 2020 and initiated August 25, 2020. Recalling firm: RLC Labs Inc.; Status: Terminated; Reported quantity: N/A; Lot: All lots with expiry between 10/2020-07/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RLC Labs Inc.
Distributor
Nationwide in the United States
Lot
All lots with expiry between 10/2020-07/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Nature-Throid, Thyroid USP [liothyronine (T3) 15.75 mcg and levothyroxine (T4) 66.5 mcg], 1.75 Grain (113.75 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3307-4; b) 60-count bottles, NDC 64727-3307-5; c) 90-count bottles, NDC 64727-3307-6; d) 100-count bottles, NDC 64727-3307-1; and e) 1,000-count bottles, NDC 64727-3307-2; Rx only, Manufactured by: RLC Labs Phoenix, AZ 85034. recalled?

Yes. FDA published recall D-1601-2020 on September 23, 2020. Reported hazard: CGMP Deviations: manufactured under the same conditions as those found to be subpotent.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail